The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
Journal of Psychopharmacology February 25, 2022 Francis M. Dijkstra, Aurora JAE van de Loo, Smedra Abdulahad et al. 16 citations
Background: Intranasal esketamine demonstrates rapid improvement of depressive symptoms. However, transient adverse effects (dissociation, sedation and dizziness) may occur, which could impact driving performance. Aims: To evaluate the effects of 84 mg intranasal esketamine on driving performance in unipolar major depressive disorder (MDD) or persistent depressive disorder (PDD) patients....